BioWorld Asia

Oct. 21, 2009

Cytos Shares Plunge as Vaccine Trial Misses Main Endpoint

Cytos Biotechnology AG lost almost one-third of its value Friday on news that its therapeutic vaccine for nicotine addiction failed to show efficacy in a Phase II study. (BioWorld International) Read More

Viriom Taking Over Development of HIV Treatments in Roche Deal

New Assay Promises Genetic Analysis of Bacterial Pathogens

Biovitrum, Biogen Idec Eye 2011 Filing for Recombinant Factor IX

Oxford BioMedica Seeks OK to Boost ProSavin Dose Level

EU Spending Watchdog Criticizes Framework Project Structures

On Heels of Expanded Merck Deal, Galapagos Raises $27M

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 16, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...